Emanuela Branchetti1, Joseph E Bavaria1, Juan B Grau1, Richard E Shaw1, Paolo Poggio1, Eric K Lai1, Nimesh D Desai1, Joseph H Gorman1, Robert C Gorman1, Giovanni Ferrari2. 1. From the Department of Surgery, Thoracic Aortic Program, Perelman School of Medicine at University of Pennsylvania, Philadelphia (E.B., J.E.B., J.B.G., P.P., E.K.L., N.D.D., J.H.G., R.C.G., G.F.); and Department of Surgery, Valley Hospital, Columbia University, Ridgewood, NJ (R.E.S.). 2. From the Department of Surgery, Thoracic Aortic Program, Perelman School of Medicine at University of Pennsylvania, Philadelphia (E.B., J.E.B., J.B.G., P.P., E.K.L., N.D.D., J.H.G., R.C.G., G.F.); and Department of Surgery, Valley Hospital, Columbia University, Ridgewood, NJ (R.E.S.). Giovanni.Ferrari@uphs.upenn.edu.
Abstract
OBJECTIVE: A total of 30% to 50% of patients with bicuspid aortic valve (BAV) require surgery for aortic valve replacement (AVR), ascending aortic replacement (AA), or both. To prevent adverse aortic events, they are risk stratified using imperfect criteria based on imaging modalities. As a result, a significant number of dissections occur outside of the parameters suggested by the guidelines. Advanced glycation end products (AGEs) are associated with valve and vascular remodeling and trigger the release of a soluble receptor (soluble receptor for advanced glycation end product [sRAGE]). This study aims to characterize sRAGE as a diagnostic and risk-stratification tool for patients with BAV referred for surgery. APPROACH AND RESULTS: sRAGE was measured in 135 patients (BAV, n=74; tricuspid aortic valve, n=61) meeting inclusion criteria from 338 enrolled patients undergoing AVR and AA. Univariate and multivariate analyses were performed. sRAGE level was significantly associated with the presence of BAV, independent of age, sex, and common risk factors for vascular disease (P<0.001). Within the BAV cohort, patients referred for AA and AVR had higher sRAGE values than patients undergoing AVR only (P=0.002). Patients with BAV <60 years of age, presenting with both valve and aortic diseases (fast progressors), had higher sRAGE than older patients who only needed AVR (slow progressors). Histological analysis showed that sRAGE correlates with dysfunctional aortic microstructure and does not correlate with aortic diameter (R(2)=0.007; P=0.51) or diameter/body surface area (R(2)=0.011; P=0.42). CONCLUSIONS: These results show that elevated level of circulating sRAGE is associated with the presence of BAV and associated aortopathies, independent of aortic diameter.
OBJECTIVE: A total of 30% to 50% of patients with bicuspid aortic valve (BAV) require surgery for aortic valve replacement (AVR), ascending aortic replacement (AA), or both. To prevent adverse aortic events, they are risk stratified using imperfect criteria based on imaging modalities. As a result, a significant number of dissections occur outside of the parameters suggested by the guidelines. Advanced glycation end products (AGEs) are associated with valve and vascular remodeling and trigger the release of a soluble receptor (soluble receptor for advanced glycation end product [sRAGE]). This study aims to characterize sRAGE as a diagnostic and risk-stratification tool for patients with BAV referred for surgery. APPROACH AND RESULTS: sRAGE was measured in 135 patients (BAV, n=74; tricuspid aortic valve, n=61) meeting inclusion criteria from 338 enrolled patients undergoing AVR and AA. Univariate and multivariate analyses were performed. sRAGE level was significantly associated with the presence of BAV, independent of age, sex, and common risk factors for vascular disease (P<0.001). Within the BAV cohort, patients referred for AA and AVR had higher sRAGE values than patients undergoing AVR only (P=0.002). Patients with BAV <60 years of age, presenting with both valve and aortic diseases (fast progressors), had higher sRAGE than older patients who only needed AVR (slow progressors). Histological analysis showed that sRAGE correlates with dysfunctional aortic microstructure and does not correlate with aortic diameter (R(2)=0.007; P=0.51) or diameter/body surface area (R(2)=0.011; P=0.42). CONCLUSIONS: These results show that elevated level of circulating sRAGE is associated with the presence of BAV and associated aortopathies, independent of aortic diameter.
Authors: Paul W M Fedak; Subodh Verma; Tirone E David; Richard L Leask; Richard D Weisel; Jagdish Butany Journal: Circulation Date: 2002-08-20 Impact factor: 29.690
Authors: Scott A LeMaire; Xinwen Wang; Jonathan A Wilks; Stacey A Carter; Shixiang Wen; Taehee Won; Dominic Leonardelli; Gobind Anand; Lori D Conklin; Xing Li Wang; Robert W Thompson; Joseph S Coselli Journal: J Surg Res Date: 2005-01 Impact factor: 2.192
Authors: Paul W M Fedak; Mauro P L de Sa; Subodh Verma; Nafiseh Nili; Pedram Kazemian; Jagdish Butany; Bradley H Strauss; Richard D Weisel; Tirone E David Journal: J Thorac Cardiovasc Surg Date: 2003-09 Impact factor: 5.209
Authors: Kathryn H Driesbaugh; Emanuela Branchetti; Juan B Grau; Samuel J Keeney; Kimberly Glass; Mark A Oyama; Nancy Rioux; Salma Ayoub; Michael S Sacks; John Quackenbush; Robert J Levy; Giovanni Ferrari Journal: J Mol Cell Cardiol Date: 2017-12-30 Impact factor: 5.000
Authors: Joshua D Hutcheson; Craig J Goergen; Frederick J Schoen; Masanori Aikawa; Peter Zilla; Elena Aikawa; Glenn R Gaudette Journal: Front Cardiovasc Med Date: 2019-02-14
Authors: Patrick Geeraert; Fatemehsadat Jamalidinan; Fiona Burns; Kelly Jarvis; Michael S Bristow; Carmen Lydell; Silvia S Hidalgo Tobon; Benito de Celis Alonso; Paul W M Fedak; James A White; Julio Garcia Journal: Front Bioeng Biotechnol Date: 2022-01-13
Authors: Paolo Poggio; Laura Cavallotti; Paola Songia; Alessandro Di Minno; Pasquale Ambrosino; Liborio Mammana; Alessandro Parolari; Francesco Alamanni; Elena Tremoli; Matteo Nicola Dario Di Minno Journal: J Am Heart Assoc Date: 2016-05-18 Impact factor: 5.501